198 related articles for article (PubMed ID: 7614683)
1. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
2. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
3. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.
Reed JA; McNutt NS; Prieto VG; Albino AP
Am J Pathol; 1994 Jul; 145(1):97-104. PubMed ID: 8030760
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization.
Sparrow LE; Heenan PJ
Australas J Dermatol; 1999 Feb; 40(1):19-24. PubMed ID: 10098284
[TBL] [Abstract][Full Text] [Related]
5. In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Schmid P; Itin P; Rufli T
Br J Dermatol; 1996 Jun; 134(6):1044-51. PubMed ID: 8763422
[TBL] [Abstract][Full Text] [Related]
6. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression.
Moretti S; Pinzi C; Berti E; Spallanzani A; Chiarugi A; Boddi V; Reali UM; Giannotti B
Melanoma Res; 1997 Aug; 7(4):313-21. PubMed ID: 9293481
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
8. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
9. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity.
Miracco C; Margherita De Santi M; Schürfeld K; Santopietro R; Lalinga AV; Fimiani M; Biagioli M; Brogi M; De Felice C; Luzi P; Andreassi L
Br J Dermatol; 2002 Mar; 146(3):399-408. PubMed ID: 11952539
[TBL] [Abstract][Full Text] [Related]
10. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
11. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
12. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
Reed JA; McNutt NS; Bogdany JK; Albino AP
J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
[TBL] [Abstract][Full Text] [Related]
13. Nuclear pseudoinclusions in melanocytic naevi and melanomas.
Rose DS
J Clin Pathol; 1995 Jul; 48(7):676-7. PubMed ID: 7560180
[TBL] [Abstract][Full Text] [Related]
14. Expression and distribution of transforming growth factor-alpha within melanocytic lesions.
Nanney LB; Coffey RJ; Ellis DL
J Invest Dermatol; 1994 Nov; 103(5):707-14. PubMed ID: 7963661
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
[TBL] [Abstract][Full Text] [Related]
16. Expression of type II transforming growth factor-beta receptor mRNA in human skin, as revealed by in situ hybridization.
Matsuura H; Myokai F; Arata J; Noji S; Taniguchi S
J Dermatol Sci; 1994 Aug; 8(1):25-32. PubMed ID: 7947489
[TBL] [Abstract][Full Text] [Related]
17. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
18. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
